person · Reporting owner
ODONNELL FRANCIS E JR
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inhibitor Therapeutics, Inc.INTI · Entity 7783 | Director · Chief Executive Officer · 10% owner | May 04, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inhibitor Therapeutics, Inc.
Report date May 04, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 150,000 |
Reported balance
After 2026-05-04 transaction · row 1
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 50,000 · Balance 150,000 F1: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIODELIVERY SCIENCES INTERNATIONAL INC
Report date May 11, 2020 · Filed May 14, 2020
Section 16 reporting ended · disclosed 2020-05-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 628,038 |
Reported balance
After 2020-05-11 transaction · row 1
1 source rowRow 1 · 2020-05-11 · Exercise / conversion · Acquired 22,500 · Balance 628,038 F1: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-05-11 | Direct | 0 |
Reported balance
After 2020-05-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-11 · Exercise / conversion · Disposed 22,500 · Balance 0 F1: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2019 Filed Mar 22, 2019 22:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-008814 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended (the EIP). The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 62,500 of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended (the EIP). The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Annual Report in March 2020. Read SEC document |
| March 01, 2019 Filed Mar 1, 2019 23:43 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 46,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005533 · doc4.xml · derivative · entry 3 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,000 shares Expires 2019-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 46,000 of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 29, 2016 under the Issuer's 2011 Equity Incentive Plan, as amended. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 46,000 of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 29, 2016 under the Issuer's 2011 Equity Incentive Plan, as amended. Read SEC document |
| March 01, 2019 Filed Mar 1, 2019 23:43 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 23,000 | $5.07 | $116,610.00 |
DisclosureSEC source: 0000899243-19-005533 · doc4.xml · nonDerivative · entry 2 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,187 F2 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F3 · price: On March 1, 2019, the Reporting Person sold an aggregate of 23,000 shares of the Issuer's Common Stock at a weighted average price of $5.07 per share. The highest sale price for the Common Stock was $5.20 per share and the lowest sale price was $4.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2019 Filed Mar 1, 2019 23:43 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 46,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005533 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 46,000 of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 29, 2016 under the Issuer's 2011 Equity Incentive Plan, as amended. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 46,000 of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 29, 2016 under the Issuer's 2011 Equity Incentive Plan, as amended. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 00:28 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $4.60 | $36,800.00 |
DisclosureSEC source: 0000899243-19-002533 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 498,187 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F3 · price: On February 1, 2019, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $4.60 per share. The highest sale price for the Common Stock was $4.68 per share and the lowest sale price was $4.52 per share. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 23:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $3.64 | $29,120.00 |
DisclosureSEC source: 0000899243-19-000559 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,187 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F3 · price: On January 2, 2019, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $3.64 per share. The highest sale price for the Common Stock was $3.75 per share and the lowest sale price was $3.54 per share. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 23:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $3.72 | $29,760.00 |
DisclosureSEC source: 0000899243-18-030074 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,187 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F3 · price: On December 3, 2018, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $3.72 per share. The highest sale price for the Common Stock was $3.78 per share and the lowest sale price was $3.60 per share. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $3.84 | $30,720.00 |
DisclosureSEC source: 0000899243-18-028048 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,187 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F3 · price: On November 1, 2018, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $3.84 per share. The highest sale price for the Common Stock was $3.93 per share and the lowest sale price was $3.70 per share. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $2.75 | $22,000.00 |
DisclosureSEC source: 0000899243-18-026093 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,187 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F3 · price: On October 1, 2018, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $2.75 per share. The highest sale price for the Common Stock was $2.83 per share and the lowest sale price was $2.71 per share. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 53,438 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-024561 · doc4.xml · derivative · entry 12 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,438 shares Expires 2018-09-13 F7 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the performance-based RSUs ("Performance RSUs") granted to the Reporting Person on February 6, 2017 under the Plan subject to certain performance measures. The remainder of the Performance RSUs under this grant will vest, in equal amounts, but subject to certain performance measures, after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 62,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-024561 · doc4.xml · derivative · entry 11 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 62,500 shares Expires 2020-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 6, 2017 under the Plan. Pursuant to a deferral, these RSUs vested on September 13, 2018. The remainder of the RSUs under this grant will vest in equal portions after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 46,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-024561 · doc4.xml · derivative · entry 10 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Underlying: Common Stock · 46,000 shares Expires 2019-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. Pursuant to a deferral, the remainder of the RSUs under this grant will vest on March 1, 2019. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 6,806 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-024561 · doc4.xml · derivative · entry 9 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,806 shares Expires 2018-09-13 F4 · kind: The shares of common stock were acquired by the Reporting Person in connection with the vesting of RSUs granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. Pursuant to a deferral, these RSUs vested on September 13, 2018. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 84,372 | $2.84 | $239,616.48 |
DisclosureSEC source: 0000899243-18-024561 · doc4.xml · nonDerivative · entry 7 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 538,187 F2 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F8 · price: On September 13, 2018, the Reporting Person sold an aggregate of 84,372 shares of the Issuer's Common Stock at a weighted average price of $2.84 per share. The highest sale price for the Common Stock was $2.90 per share and the lowest sale price was $2.90 per share. F9 · price: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 53,438 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-024561 · doc4.xml · nonDerivative · entry 6 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 622,559 F7 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the performance-based RSUs ("Performance RSUs") granted to the Reporting Person on February 6, 2017 under the Plan subject to certain performance measures. The remainder of the Performance RSUs under this grant will vest, in equal amounts, but subject to certain performance measures, after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-024561 · doc4.xml · nonDerivative · entry 5 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 569,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. Pursuant to a deferral, the remainder of the RSUs under this grant will vest on March 1, 2019. F6 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 6, 2017 under the Plan. Pursuant to a deferral, these RSUs vested on September 13, 2018. The remainder of the RSUs under this grant will vest in equal portions after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 46,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-024561 · doc4.xml · nonDerivative · entry 4 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. Pursuant to a deferral, the remainder of the RSUs under this grant will vest on March 1, 2019. F5 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. Pursuant to a deferral, the remainder of the RSUs under this grant will vest on March 1, 2019. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 6,806 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-024561 · doc4.xml · nonDerivative · entry 3 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,621 F4 · price: The shares of common stock were acquired by the Reporting Person in connection with the vesting of RSUs granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. Pursuant to a deferral, these RSUs vested on September 13, 2018. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 133,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-024561 · doc4.xml · derivative · entry 8 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 133,333 shares Expires 2018-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 133,333 of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 23, 2015 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 12, 2018. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 66,667 | $2.83 | $188,667.61 |
DisclosureSEC source: 0000899243-18-024561 · doc4.xml · nonDerivative · entry 2 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,815 F2 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F3 · price: On September 12, 2018, the Reporting Person sold an aggregate of 66,667 shares of the Issuer's Common Stock at a weighted average price of $2.83 per share. The highest sale price for the Common Stock was $2.85 per share and the lowest sale price was $2.80 per share. F9 · price: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 22:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 133,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-024561 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 133,333 of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 23, 2015 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 12, 2018. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 133,333 of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 23, 2015 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 12, 2018. Read SEC document |
| August 17, 2018 Filed Aug 21, 2018 21:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 8,000 | $2.79 | $22,320.00 |
DisclosureSEC source: 0000899243-18-022886 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,149 F2 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F3 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F1 · price: On August 17, 2018, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $2.79 per share. The highest sale price for the Common Stock was $2.85 per share and the lowest sale price was $2.75 per share. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 23:32 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionStock Option · Derivative | 37,500 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0000899243-18-018489 · doc4.xml · derivative · entry 3 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2018-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 23:32 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Tax withholdingCommon Stock | 27,525 | $3.10 | $85,327.50 |
DisclosureSEC source: 0000899243-18-018489 · doc4.xml · nonDerivative · entry 2 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,149 Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 23:32 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 37,500 | $2.01 | $75,375.00 |
DisclosureSEC source: 0000899243-18-018489 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person acquired the shares through a cashless exercise under the Issuer's Amended and Restated 2001 Incentive Plan. The Reporting Person exercised a total of 37,500 options and received 9,975 shares of common stock. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 23:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 133,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006982 · doc4.xml · derivative · entry 8 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,333 Underlying: Common Stock · 133,333 shares Expires 2018-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on March 8, 2018. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on September 12, 2018. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 23:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 66,666 | $2.14 | $142,665.24 |
DisclosureSEC source: 0000899243-18-006982 · doc4.xml · nonDerivative · entry 5 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,174 F3 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F6 · price: On March 8, 2018, the Reporting Person sold an aggregate of 66,666 shares of the Issuer's Common Stock at a weighted average price of $2.14 per share. The highest sale price for the Common Stock was $2.18 per share and the lowest sale price was $2.10 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 23:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 133,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006982 · doc4.xml · nonDerivative · entry 4 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on March 8, 2018. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on September 12, 2018. F5 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on March 8, 2018. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on September 12, 2018. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 23:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 46,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006982 · doc4.xml · derivative · entry 7 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,000 Underlying: Common Stock · 46,000 shares Expires 2019-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on each of (i) September 13, 2018 and (ii) March 1, 2019. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 23:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 48,418 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006982 · doc4.xml · derivative · entry 6 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,418 shares Expires 2018-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 48,418 of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on March 7, 2018. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 23:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 47,210 | $2.13 | $100,557.30 |
DisclosureSEC source: 0000899243-18-006982 · doc4.xml · nonDerivative · entry 3 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,507 F3 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F4 · price: On March 7, 2018, the Reporting Person sold an aggregate of 47,210 shares of the Issuer's Common Stock at a weighted average price of $2.13 per share. The highest sale price for the Common Stock was $2.20 per share and the lowest sale price was $2.10 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 23:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 46,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006982 · doc4.xml · nonDerivative · entry 2 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on each of (i) September 13, 2018 and (ii) March 1, 2019. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on each of (i) September 13, 2018 and (ii) March 1, 2019. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 23:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 48,418 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006982 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 48,418 of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on March 7, 2018. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 48,418 of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on March 7, 2018. Read SEC document |
| February 18, 2018 Filed Feb 24, 2018 00:21 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 45,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-005381 · doc4.xml · derivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2021-03-19 F1 · kind: The RSUs were issued to the Reporting Person on February 18, 2018, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended. The award is subject to time-based vesting and will vest as follows: (i) one-third vests on the first open trading window of 2019; (ii) one-third vests on the date of the first open trading window of 2020; and (iii) the remaining third vests on the first open trading window of 2021. Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A. F1 · derivative.exercise_date: The RSUs were issued to the Reporting Person on February 18, 2018, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended. The award is subject to time-based vesting and will vest as follows: (i) one-third vests on the first open trading window of 2019; (ii) one-third vests on the date of the first open trading window of 2020; and (iii) the remaining third vests on the first open trading window of 2021. Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 22:03 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 750 | $1.90 | $1,425.00 |
DisclosureSEC source: 0000899243-17-008551 · doc4.xml · nonDerivative · entry 2 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,299 F2 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 22:03 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 2,520 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-008551 · doc4.xml · derivative · entry 3 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,520 shares Expires 2017-03-22 F1 · kind: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 22:03 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 2,520 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-008551 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,049 F1 · price: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Read SEC document |
| February 17, 2017 Filed Feb 24, 2017 23:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 6,416 | $1.85 | $11,869.60 |
DisclosureSEC source: 0000899243-17-005252 · doc4.xml · nonDerivative · entry 7 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,529 F5 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. Read SEC document |
| February 16, 2017 Filed Feb 24, 2017 23:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 83,900 | $1.89 | $158,571.00 |
DisclosureSEC source: 0000899243-17-005252 · doc4.xml · nonDerivative · entry 6 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,945 F5 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F7 · price: On February 16, 2017, the Reporting Person sold an aggregate of 83,900 shares of the Issuer's Common Stock at a weighted average price of $1.89 per share. The highest sale price for the Common Stock was $1.95 per share and the lowest sale price was $1.85 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2017 Filed Feb 24, 2017 23:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 133,334 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005252 · doc4.xml · derivative · entry 11 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,666 Underlying: Common Stock · 133,334 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on February 15, 2017. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on each of (i) September 14, 2017 and (ii) February 23, 2018. Read SEC document |
| February 15, 2017 Filed Feb 24, 2017 23:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 48,419 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005252 · doc4.xml · derivative · entry 10 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,418 Underlying: Common Stock · 48,419 shares Expires 2017-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on February 15, 2017. Pursuant to a deferral, the remaining half of the RSUs under this grant will vest on September 13, 2017. Read SEC document |
| February 15, 2017 Filed Feb 24, 2017 23:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 70,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005252 · doc4.xml · derivative · entry 9 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 70,000 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on February 15, 2017. Read SEC document |
| February 15, 2017 Filed Feb 24, 2017 23:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 7,965 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005252 · doc4.xml · derivative · entry 8 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,965 shares Expires 2017-02-15 F1 · kind: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Pursuant to a deferral, these RSUs vested on February 15, 2017. Read SEC document |
| February 15, 2017 Filed Feb 24, 2017 23:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 39,544 | $1.95 | $77,110.80 |
DisclosureSEC source: 0000899243-17-005252 · doc4.xml · nonDerivative · entry 5 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,845 F5 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F6 · price: On February 15, 2017, the Reporting Person sold an aggregate of 39,544 shares of the Issuer's Common Stock at a weighted average price of $1.95 per share. The highest sale price for the Common Stock was $2.00 per share and the lowest sale price was $1.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2017 Filed Feb 24, 2017 23:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 133,334 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005252 · doc4.xml · nonDerivative · entry 4 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on February 15, 2017. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on each of (i) September 14, 2017 and (ii) February 23, 2018. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on February 15, 2017. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on each of (i) September 14, 2017 and (ii) February 23, 2018. Read SEC document |
| February 15, 2017 Filed Feb 24, 2017 23:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 48,419 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005252 · doc4.xml · nonDerivative · entry 3 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on February 15, 2017. Pursuant to a deferral, the remaining half of the RSUs under this grant will vest on September 13, 2017. F3 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on February 15, 2017. Pursuant to a deferral, the remaining half of the RSUs under this grant will vest on September 13, 2017. Read SEC document |
| February 15, 2017 Filed Feb 24, 2017 23:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005252 · doc4.xml · nonDerivative · entry 2 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 70,000 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on February 15, 2017. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 70,000 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on February 15, 2017. Read SEC document |
| February 15, 2017 Filed Feb 24, 2017 23:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 7,965 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005252 · doc4.xml · nonDerivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,636 F1 · price: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Pursuant to a deferral, these RSUs vested on February 15, 2017. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 23:04 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 187,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-003155 · doc4.xml · derivative · entry 1 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2020-03-18 F1 · kind: The RSUs were issued to the Reporting Person on February 6, 2017, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended. The award is subject to time-based vesting and will vest as follows: (i) one-third vests on the later to occur of March 1, 2018 or the first open trading window of 2018; (ii) one-third vests on the date of the first open trading window of 2019; and (iii) the remaining third vests on the first open trading window of 2020. Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A. The issuance of these RSUs is subject to shareholder approval at the 2017 Annual Meeting of Stockholders. F1 · derivative.exercise_date: The RSUs were issued to the Reporting Person on February 6, 2017, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended. The award is subject to time-based vesting and will vest as follows: (i) one-third vests on the later to occur of March 1, 2018 or the first open trading window of 2018; (ii) one-third vests on the date of the first open trading window of 2019; and (iii) the remaining third vests on the first open trading window of 2020. Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A. The issuance of these RSUs is subject to shareholder approval at the 2017 Annual Meeting of Stockholders. Read SEC document |
| September 23, 2016 Filed Sep 23, 2016 22:32 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 50,000 | $2.68 | $134,000.00 |
DisclosureSEC source: 0000899243-16-029944 · doc4.xml · nonDerivative · entry 2 ODONNELL FRANCIS E JR · CIK 0001066040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HCG II, LLC Disclosed balance after: 1,285,490 F4 · price: On September 23, 2016, HCGII sold an aggregate of 50,000 shares of the Issuer's Common Stock at a weighted average price of $2.68 per share. The highest sale price for the Common Stock was $2.81 per share and the lowest sale price was $2.58 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Represents all of the shares of the Issuer held by HCGII. F3 · ownership.nature: The shares are owned by HCGII. The Reporting Person is a discretionary beneficiary of an irrevocable spendthrift trust which directly owns a minority membership interest in HCGII. The Reporting Person disclaims ownership of all securities held by HCGII. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.